within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AD02_Alteplase;

model Alteplase
  extends Pharmacolibrary.Drugs.ATC.B.B01AD02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alteplase is a recombinant tissue plasminogen activator (rt-PA) used for thrombolytic therapy. It is mainly indicated for the treatment of acute ischemic stroke, myocardial infarction, and pulmonary embolism and is approved for use in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult healthy volunteers and patients, typically following intravenous bolus or infusion administration.</p><h4>References</h4><ol><li><p>Wang, L, et al., &amp; Xiong, Y (2024). Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> 13(9) e031692–None. DOI:<a href=\"https://doi.org/10.1161/JAHA.123.031692\">10.1161/JAHA.123.031692</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38686848/\">https://pubmed.ncbi.nlm.nih.gov/38686848</a></p></li><li><p>Glund, S, et al., &amp; Wolff, M (2023). Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study. <i>Clinical pharmacokinetics</i> 62(7) 1023–1030. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01253-3\">10.1007/s40262-023-01253-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37248330/\">https://pubmed.ncbi.nlm.nih.gov/37248330</a></p></li><li><p>Larrue, V (2005). Intravenous alteplase for acute ischaemic stroke. <i>Expert opinion on pharmacotherapy</i> 6(15) 2699–2709. DOI:<a href=\"https://doi.org/10.1517/14656566.6.15.2699\">10.1517/14656566.6.15.2699</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16316308/\">https://pubmed.ncbi.nlm.nih.gov/16316308</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Alteplase;
